Related references
Note: Only part of the references are listed.Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1
Ulf Landmesser et al.
CARDIOVASCULAR RESEARCH (2021)
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36
Zhiyong Qi et al.
CIRCULATION (2021)
Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
Piotr Peczek et al.
LIFE-BASEL (2021)
Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall
Yanan Guo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
PCSK9: Associated with cardiac diseases and their risk factors?
Yanan Guo et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2021)
PCSK9 and atherosclerosis: Looking beyond LDL regulation
Rosetta Ragusa et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2021)
PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling
Valentina Scalise et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Platelet-Derived PCSK9 Is Associated with LDL Metabolism and Modulates Atherothrombotic Mechanisms in Coronary Artery Disease
Alvaro Petersen-Uribe et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Role of PAI-1 in hepatic steatosis and dyslipidemia
Joshua A. Levine et al.
SCIENTIFIC REPORTS (2021)
Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects
Antonio Nenna et al.
BIOMED RESEARCH INTERNATIONAL (2021)
Pleiotropic Effects of PCSK-9 Inhibitors
Marcin Basiak et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications
Xiao-dan Xia et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study
Jia Peng et al.
THROMBOSIS JOURNAL (2021)
Inhibitors of Protein Convertase Subtilisin/Kexin 9 (PCSK9) and Acute Coronary Syndrome (ACS): The State-of-the-Art
Gabriella Iannuzzo et al.
JOURNAL OF CLINICAL MEDICINE (2021)
PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
Aureli Luquero et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
PCSK9 Biology and Its Role in Atherothrombosis
Cristina Barale et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Lipid-Lowering Therapy and Hemorrhagic Stroke Risk Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
Borja E. Sanz-Cuesta et al.
STROKE (2021)
PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
Sai Sahana Sundararaman et al.
BIOMEDICINES (2021)
Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up
Cristina Barale et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Blood flow patterns regulate PCSK9 secretion viaMyD88-mediated pro-inflammatory cytokines
Shijie Liu et al.
CARDIOVASCULAR RESEARCH (2020)
PCSK9 and inflammation: role of shear stress, pro-inflammatory cytokines, and LOX-1
Zufeng Ding et al.
CARDIOVASCULAR RESEARCH (2020)
Lipoprotein receptor signalling in atherosclerosis
Chieko Mineo
CARDIOVASCULAR RESEARCH (2020)
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
Proprotein Convertase Subtilisin/Kexin Type 9, Angiopoietin-Like Protein 8, Sortilin, and Cholesteryl Ester Transfer Protein-Friends of Foes for Psoriatic Patients at the Risk of Developing Cardiometabolic Syndrome?
Julita Anna Krahel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation
Vittoria Cammisotto et al.
ANTIOXIDANTS (2020)
Tissue factor in atherosclerosis and atherothrombosis
Steven P. Grover et al.
ATHEROSCLEROSIS (2020)
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study
David M. Leistner et al.
EUROPEAN HEART JOURNAL (2020)
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Julius L. Katzmann et al.
FRONTIERS IN PHYSIOLOGY (2020)
Response by Marston et al to Letter Regarding Article, The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism
Nicholas A. Marston et al.
CIRCULATION (2020)
PCSK9: A novel inflammation modulator in atherosclerosis?
Zhi-Han Tang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Dyslipidemia induced inflammatory status, platelet activation and endothelial dysfunction in rabbits: Protective role of 10-Dehydrogingerdione
Mohamed Mahmoud El-Seweidy et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice
Susanne Schuster et al.
SCIENTIFIC REPORTS (2019)
PCSK9 and inflammation: a review of experimental and clinical evidence
Amir Abbas Momtazi-Borojeni et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
PCSK9 Antibody Alirocumab Attenuates Arterial Wall Inflammation Without Changes in Circulating Inflammatory Markers
Renate M. Hoogeveen et al.
JACC-CARDIOVASCULAR IMAGING (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Effect of statins on measures of coagulation: potential role of low-density lipoprotein receptors
Francesco Paciullo et al.
EUROPEAN HEART JOURNAL (2019)
High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor
I. M. Rietveld et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
New Insight on a Combination of Policosanol and 10-Dehydrogingerdione Phytochemicals as Inhibitors for Platelet Activation Biomarkers and Atherogenicity Risk in Dyslipidemic Rabbits: Role of CETP and PCSK9 Inhibition
Mohamed Mahmoud Elseweidy et al.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY (2018)
Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis
Steven P. Grover et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Rosuvastatin use improvesmeasures of coagulation in patients with venous thrombosis
Joseph S. Biedermann et al.
EUROPEAN HEART JOURNAL (2018)
The therapeutic potential of CETP inhibitors: a patent review
Xinran Wang et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
PCSK9 as a Positive Modulator of Platelet Activation
Marina Camera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Oxidized low-density lipoprotein in inflammation-driven thrombosis
G. Obermayer et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia
Suzanne Schol-Gelok et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Research Progress on the Relationship between Atherosclerosis and Inflammation
Yuhua Zhu et al.
BIOMOLECULES (2018)
Ezetimibe inhibits platelet activation and uPAR expression on endothelial cells
Tobias Becher et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study
Eliano P. Nayarese et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Exploration of PCSK9 as a Cardiovascular Risk Factor Is There a Link to the Platelet?
Paul A. Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Relationship of PCSK9 and Urinary Thromboxane Excretion to Cardiovascular Events in Patients With Atrial Fibrillation
Daniele Pastori et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-analysis of the Literature
Francesco Dentali et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2017)
Impact of high-dose statins on vitamin D levels and platelet function in patients with coronary artery disease
Monica Verdoia et al.
THROMBOSIS RESEARCH (2017)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) Deficiency is Protective Against Venous Thrombosis in Mice
Hui Wang et al.
SCIENTIFIC REPORTS (2017)
Diminished neutrophil extracellular trap (NET) formation is a novel innate immune deficiency induced by acute ethanol exposure in polymicrobial sepsis, which can be rescued by CXCL1
Liliang Jin et al.
PLOS PATHOGENS (2017)
Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis
Setor K. Kunutsor et al.
LANCET HAEMATOLOGY (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
Increased Mean Platelet Volume in Familial Hypercholesterolemia
Atilla Icli et al.
ANGIOLOGY (2016)
Local effects of human PCSK9 on the atherosclerotic lesion
Ilaria Giunzioni et al.
JOURNAL OF PATHOLOGY (2016)
Novel phosphatidylethanolamine derivatives accumulate in circulation in hyperlipidemic ApoE-/- mice and activate platelets via TLR2
Sudipta Biswas et al.
BLOOD (2016)
DIFFERENTIAL EXPRESSION OF PCSK9 MODULATES INFECTION, INFLAMMATION, AND COAGULATION IN A MURINE MODEL OF SEPSIS
Dhruva J. Dwivedi et al.
SHOCK (2016)
The impact of statin therapy on plasma levels of von Willebrand factor antigen Systematic review and meta-analysis of randomised placebo-controlled trials
Amirhossein Sahebkar et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Tissue factor as a link between inflammation and coagulation
Marco Witkowski et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2016)
The emerging Role of NeTs in venous Thrombosis and immunothrombosis
Andrew S. Kimball et al.
FRONTIERS IN IMMUNOLOGY (2016)
LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
Eguzkine Ochoa et al.
PLOS ONE (2016)
Hemodynamic Shear Stress via ROS Modulates PCSK9 Expression in Human Vascular Endothelial and Smooth Muscle Cells and Along the Mouse Aorta
Zufeng Ding et al.
ANTIOXIDANTS & REDOX SIGNALING (2015)
Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade
Simbarashe Magwenzi et al.
BLOOD (2015)
The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients with Stable Coronary Artery Disease
Sha Li et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2015)
Tissue Factor and Atherothrombosis
Kohei Tatsumi et al.
Journal of Atherosclerosis and Thrombosis (2015)
Is lipid lowering therapy an independent risk factor for venous thromboembolism? A population-based case-control study
Aneel A. Ashrani et al.
THROMBOSIS RESEARCH (2015)
Low-Density Lipoprotein Receptor-Related Protein-1 Role in the Regulation of Vascular Integrity
Dudley K. Strickland et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2014)
LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism
Roberto Carnevale et al.
ATHEROSCLEROSIS (2014)
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy
L. M. Camargo et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
High-density lipoprotein as a modulator of platelet and coagulation responses
Marco van der Stoep et al.
CARDIOVASCULAR RESEARCH (2014)
Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease
Yan Zhang et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2014)
Low Levels of Low-Density Lipoprotein-C Associated With Proprotein Convertase Subtilisin Kexin 9 Inhibition Do Not Increase the Risk of Hemorrhagic Transformation
Alexy Tran-Dinh et al.
STROKE (2014)
The Effects of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Platelet and Inflammatory Biomarkers in Patients with Metabolic Syndrome
Michael Miller et al.
CARDIOLOGY (2013)
Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for the Treatment of Dyslipidemia and Atherosclerosis
Daniel Urban et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
Inflammation in Atherosclerosis
Peter Libby
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
Lipid parameters, lipid lowering drugs and the risk of venous thromboembolism
Aurelien Delluc et al.
ATHEROSCLEROSIS (2012)
Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels
Nicola Ferri et al.
ATHEROSCLEROSIS (2012)
Elevated factor VIII levels and risk of venous thrombosis
P. Vince Jenkins et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin
A. Phillip Owens et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk
Philip J. Barter et al.
JOURNAL OF LIPID RESEARCH (2012)
Exposure of Endothelial Cells to Physiological Levels of Myeloperoxidase-Modified LDL Delays Pericellular Fibrinolysis
Karim Zouaoui Boudjeltia et al.
PLOS ONE (2012)
Lipoprotein(a): Cellular Effects and Molecular Mechanisms
Kirsten Riches et al.
CHOLESTEROL (2012)
Inherited Human gp91phox Deficiency Is Associated With Impaired Isoprostane Formation and Platelet Dysfunction
Pasquale Pignatelli et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
HDL scavenger receptor class B type I and platelet function
Jerzy-Roch Nofer et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia
Yi Ma et al.
BLOOD (2010)
High-density lipoproteins, platelets and the pathogenesis of atherosclerosis
Jerzy-Roch Nofer et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2010)
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis
A. S. Ramcharan et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin
Osamah Hussein et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Mechanisms of disease:: Platelet activation and atherothrombosis
Giovanni Davi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Eugene A. Podrez et al.
NATURE MEDICINE (2007)
Platelet integrin αIIbβ3:: activation mechanisms
Y.-Q. Ma et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse
Cheryl D. Overton et al.
CIRCULATION RESEARCH (2007)
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone - Is sufficient cholesterol-lowering enough to inhibit platelets?
Michael Piorkowski et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Lipoprotein(a) and thrombocytes: Potential mechanisms underlying cardiovascular risk
William Discepolo et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2006)
LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo
N Bovenschen et al.
BLOOD (2005)
Elevated levels of FVIII : C within families are associated with an increased risk for venous and arterial thrombosis
I Bank et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction
NK Kaba et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Regulation of platelet adhesion by oxidized lipoproteins and oxidized phospholipids
J Hartwich et al.
PLATELETS (2002)
Activation-dependent surface expression of LOX-1 in human platelets
MY Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Thrombus formation on atherosclerotic plaques: Pathogenesis and clinical consequences
U Rauch et al.
ANNALS OF INTERNAL MEDICINE (2001)
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins
U Rauch et al.
ATHEROSCLEROSIS (2000)
Share Paper
